129 related articles for article (PubMed ID: 12425151)
1. [Cevimeline hydrochloride hydrate (Saligren capsule 30 mg): a review of its pharmacological profiles and clinical potential in xerostomia].
Shiozawa A
Nihon Yakurigaku Zasshi; 2002 Oct; 120(4):253-8. PubMed ID: 12425151
[TBL] [Abstract][Full Text] [Related]
2. Effects of pilocarpine hydrochloride and cevimeline on submandibular/sublingual salivation in rat xerostomia model produced by X-ray irradiation.
Omori Y; Asari T; Maruyama K; Kusama H; Kojima M; Shibata N
Arzneimittelforschung; 2003; 53(5):342-50. PubMed ID: 12854361
[TBL] [Abstract][Full Text] [Related]
3. Effects of cevimeline on the immunolocalization of aquaporin-5 and the ultrastructure of salivary glands in Sjögren's syndrome model mice.
Nishimura H; Yakeishi A; Saga T; Yamaki K
Kurume Med J; 2009; 56(3-4):39-47. PubMed ID: 20505281
[TBL] [Abstract][Full Text] [Related]
4. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 2nd communication: effects on somatic nervous system and on autonomic nervous system and smooth muscle.
Arisawa H; Fukui K; Fujise N; Masunaga H
Arzneimittelforschung; 2002; 52(2):81-8. PubMed ID: 11878203
[TBL] [Abstract][Full Text] [Related]
5. A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca.
Petrone D; Condemi JJ; Fife R; Gluck O; Cohen S; Dalgin P
Arthritis Rheum; 2002 Mar; 46(3):748-54. PubMed ID: 11920411
[TBL] [Abstract][Full Text] [Related]
6. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 1st communication: effects on general behavior and central nervous system.
Arisawa H; Imai E; Fujise N; Fukui K; Masunaga H
Arzneimittelforschung; 2002; 52(1):14-20. PubMed ID: 11838269
[TBL] [Abstract][Full Text] [Related]
7. Use of muscarinic agonists in the treatment of Sjögren's syndrome.
Fox RI; Konttinen Y; Fisher A
Clin Immunol; 2001 Dec; 101(3):249-63. PubMed ID: 11726216
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sjögren's syndrome in southern Chinese patients: a randomised double-blind, placebo-controlled crossover study.
Leung KC; McMillan AS; Wong MC; Leung WK; Mok MY; Lau CS
Clin Rheumatol; 2008 Apr; 27(4):429-36. PubMed ID: 17899308
[TBL] [Abstract][Full Text] [Related]
9. An immunohistochemistry-based study on aquaporin (AQP)-1, 3, 4, 5 and 8 in the parotid glands, submandibular glands and sublingual glands of Sjögren's syndrome mouse models chronically administered cevimeline.
Nakamura M; Saga T; Watanabe K; Takahashi N; Tabira Y; Kusukawa J; Yamaki K
Kurume Med J; 2013; 60(1):7-19. PubMed ID: 23925155
[TBL] [Abstract][Full Text] [Related]
10. [Clinical significance of cevimeline hydrochloride in the treatment of dry mouth in patients with Sjögren's syndrome].
Ogawa N; Shimoyama K; Karasawa H; Fukushima T; Masaki Y; Wano Y; Hirose Y; Sugai S
Nihon Rinsho Meneki Gakkai Kaishi; 2004 Oct; 27(5):330-7. PubMed ID: 15559322
[TBL] [Abstract][Full Text] [Related]
11. [The effectiveness of cevimeline hydrochloride on dry cough in Sjögren's syndrome].
Nishinarita M; Hanzawa M; Iikuni N; Ota S
Nihon Rinsho Meneki Gakkai Kaishi; 2004 Apr; 27(2):99-102. PubMed ID: 15164930
[TBL] [Abstract][Full Text] [Related]
12. Efficacy prediction of cevimeline in patients with Sjögren's syndrome.
Yamada H; Nakagawa Y; Wakamatsu E; Sumida T; Yamachika S; Nomura Y; Mishima K; Saito I
Clin Rheumatol; 2007 Aug; 26(8):1320-7. PubMed ID: 17221146
[TBL] [Abstract][Full Text] [Related]
13. Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial.
Fife RS; Chase WF; Dore RK; Wiesenhutter CW; Lockhart PB; Tindall E; Suen JY
Arch Intern Med; 2002 Jun; 162(11):1293-300. PubMed ID: 12038948
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: a randomized, double-blind clinical study.
Ono M; Takamura E; Shinozaki K; Tsumura T; Hamano T; Yagi Y; Tsubota K
Am J Ophthalmol; 2004 Jul; 138(1):6-17. PubMed ID: 15234277
[TBL] [Abstract][Full Text] [Related]
15. (+/-)-cis-2-methylspiro[1,3-oxathiolane-5,3'-quinuclidine] hydrochloride, hemihydrate (SNI-2011, cevimeline hydrochloride) induces saliva and tear secretions in rats and mice: the role of muscarinic acetylcholine receptors.
Iga Y; Arisawa H; Ogane N; Saito Y; Tomizuka T; Nakagawa-Yagi Y; Masunaga H; Yasuda H; Miyata N
Jpn J Pharmacol; 1998 Nov; 78(3):373-80. PubMed ID: 9869272
[TBL] [Abstract][Full Text] [Related]
16. Cevimeline.
Weber J; Keating GM
Drugs; 2008; 68(12):1691-8. PubMed ID: 18681491
[TBL] [Abstract][Full Text] [Related]
17. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 4th communication: Effects on gastrointestinal, urinary and reproductive systems and other effects.
Arisawa H; Fukui K; Imai E; Fujise N; Masunaga H
Arzneimittelforschung; 2002; 52(4):225-32. PubMed ID: 12040964
[TBL] [Abstract][Full Text] [Related]
18. Use of cevimeline, a muscarinic M1 and M3 agonist, in the treatment of Sjögren's syndrome.
Fox RI
Adv Exp Med Biol; 2002; 506(Pt B):1107-16. PubMed ID: 12614037
[No Abstract] [Full Text] [Related]
19. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 3rd communication: effects on respiratory and cardiovascular systems.
Arisawa H; Fukui K; Masunaga H
Arzneimittelforschung; 2002; 52(3):162-7. PubMed ID: 11963642
[TBL] [Abstract][Full Text] [Related]
20. Sjögren's syndrome patients presenting with hypergammaglobulinemia are relatively unresponsive to cevimeline treatment.
Komai K; Shiozawa K; Tanaka Y; Yoshihara R; Tanaka C; Sakai H; Yamane T; Murata M; Tsumiyama K; Hashiramoto A; Shiozawa S
Mod Rheumatol; 2009; 19(4):416-9. PubMed ID: 19452244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
